

Get Clarity On Generics

Cost-Effective CT & MRI Contrast Agents

**FRESENIUS
KABI**

[WATCH VIDEO](#)

AJNR

This information is current as
of August 19, 2025.

Efficacy and Safety of the Woven EndoBridge (WEB) Device for the Treatment of Intracranial Aneurysms: A Systematic Review and Meta-Analysis

S. Asnafi, A. Rouchaud, L. Pierot, W. Brinjikji, M.H. Murad and D.F. Kallmes

AJNR Am J Neuroradiol 2016, 37 (12) 2287-2292

doi: <https://doi.org/10.3174/ajnr.A4900>

<http://www.ajnr.org/content/37/12/2287>

Efficacy and Safety of the Woven EndoBridge (WEB) Device for the Treatment of Intracranial Aneurysms: A Systematic Review and Meta-Analysis

 S. Asnafi,  A. Rouchaud,  L. Pierot,  W. Brinjikji,  M.H. Murad, and  D.F. Kallmes



ABSTRACT

BACKGROUND AND PURPOSE: Intrasaccular flow diverters are increasingly being used in the treatment of wide-neck and bifurcation aneurysms. We performed a systematic review and meta-analysis of existing literature on the Woven EndoBridge device in the treatment of intracranial aneurysms.

MATERIALS AND METHODS: A comprehensive literature search was performed through October 1, 2015. We extracted information on baseline aneurysm and patient characteristics. Outcomes studied included immediate and midterm (>3 month) angiographic outcomes (complete occlusion as well as adequate occlusion, defined as complete occlusion or neck remnant), aneurysm retreatment, intraoperative rupture, perioperative morbidity and mortality, thromboembolic complications, and treatment failure. Meta-analysis was performed by using the random-effects model.

RESULTS: Fifteen uncontrolled series were included in this analysis, including 565 patients with 588 aneurysms, of which 127 were ruptured. Initial complete and adequate occlusion rates were 27% (95% CI, 15%–39%) and 59% (95% CI, 39%–78%), respectively. Midterm complete and adequate occlusion rates after a median of 7 months were 39% (95% CI, 26%–52%) and 85% (95% CI, 78%–91%), respectively. Perioperative morbidity and mortality rates were 4% (95% CI, 1%–8%) and 1% (95% CI, 0%–2%), respectively. Midterm adequate occlusion rates for ruptured aneurysms were 85% (95% CI, 67%–98%), compared with 84% (95% CI, 72%–94%) for unruptured aneurysms ($P = .89$). Patients with ruptured aneurysm had similar rates of perioperative morbidity to patients with unruptured aneurysm (2%; 95% CI, 0%–26% versus 2%; 95% CI, 0%–6%, respectively; $P = .35$).

CONCLUSIONS: Early evidence derived from uncontrolled studies suggests that Woven EndoBridge treatment has a good safety profile and promising rates of adequate occlusion, especially given the complexity of aneurysms treated. Further prospective clinical trials are needed to confirm these results and better define the risks and benefits of use of the Woven EndoBridge device in treating wide-neck and wide-neck bifurcation aneurysms.

ABBREVIATION: WEB = Woven EndoBridge

With the advent of stent-assisted and balloon-assisted coiling, wide-neck and wide-neck bifurcation intracranial aneurysms are increasingly treated with endovascular techniques. Both stent-assisted and balloon-assisted coiling have been shown safe and effective in treating these aneurysms by allowing for increased packing and lower rates of parent artery occlusion com-

pared with conventional coiling alone.^{1–7} However, because of less than satisfactory occlusion rates with coil embolization of wide-neck and wide-neck bifurcation aneurysms, there has been a push toward treating these lesions with intrasaccular and intraluminal flow diverters.

The Woven EndoBridge (WEB; Sequent Medical, Aliso Viejo, California) is a nitinol braided-wire intravascular device designed to disrupt blood flow at the aneurysmal neck. This device is specifically designed for the treatment of wide-neck bifurcation aneurysms.^{8,9} To date, several case series have demonstrated that the WEB device is both safe and effective in treatment of wide-neck and wide-neck bifurcation aneurysms.^{10–13} We present the results of a systematic review and meta-analysis examining outcomes of endovascular treatment of wide-neck and wide-neck bifurcation aneurysms with the WEB device. The aim of our study was to assess both angiographic and clinical outcomes.

Received April 4, 2016; accepted after revision June 24.

From the Department of Radiology (S.A., A.R., W.B., D.F.K.) and Center for the Science of Healthcare Delivery (M.H.M.), Mayo Clinic, Rochester, Minnesota; and Department of Neuroradiology (L.P.), Maison Blanche Hospital, University of Reims Champagne-Ardenne, Reims, France.

Please address correspondence to Waleed Brinjikji, MD, Department of Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905; e-mail: brinjikji.waleed@mayo.edu; @wbrinjikji

 Indicates article with supplemental on-line table.

<http://dx.doi.org/10.3174/ajnr.A4900>

MATERIALS AND METHODS

Literature Search

A comprehensive literature search of 3 data bases (PubMed, Ovid MEDLINE, and Ovid EMBASE) was designed and conducted by an experienced librarian with input from the authors. The keywords “intracranial aneurysm,” “cerebral aneurysm,” “aneurysm,” “wide-neck,” “bifurcation,” “WEB device,” and “intraluminal flow diverter” were used in both “AND” and “OR” combinations. The search was limited to articles published from January 1, 2010, to October 1, 2015, and was supplemented by contacting experts in the field for any additional studies. All studies reporting patients with aneurysms treated with the WEB device were included. Inclusion criteria were the following: 1) English language, 2) study reporting a consecutive series of aneurysms treated with the WEB device, and 3) series of at least 5 patients reporting angiographic and/or clinical outcomes. Review articles, comments, guidelines, technical notes, and editorials were excluded. Two of the authors selected the included studies. A third author arbitrated in cases of disagreement.

Outcomes and Data Extraction

For each study, we extracted the following baseline information: number of patients, aneurysm rupture status, patient sex, mean age, use of core lab in assessing angiographic outcomes, number of aneurysms treated, mean aneurysm size, mean aneurysm neck size, length of clinical follow-up, and length of angiographic follow-up.

Outcomes studied included immediate and midterm (>3 month) angiographic outcomes (complete occlusion and adequate occlusion, which was defined as complete occlusion or neck remnant), aneurysm retreatment, intraoperative rupture, perioperative morbidity and mortality, thromboembolic complication, and treatment failure. Treatment failure was defined as a failed attempt at WEB device placement. Outcomes were calculated for the overall patient population with subgroup analysis by rupture status (ruptured versus unruptured). Morbidity was defined as mRS score >1. There were variable classification scales to assess aneurysm occlusion used in this study. For studies that used the WEB Occlusion Scale, complete occlusion was defined as no contrast opacification of the aneurysm with or without contrast opacification of the proximal recess of the device. Earlier studies that did not use the WEB Occlusion Scale and used the Raymond scale instead often classified contrast opacification of the proximal recess of the device as a neck remnant or did not specify recess opacification rates. Thus, for the purposes of this meta-analysis, we report adequate occlusion, which was defined as complete occlusion or neck remnant (complete occlusion with opacification of the neck).

Study Risk of Bias

We modified the Newcastle-Ottawa Quality Assessment Scale for Case Control Studies to assess the risk of bias of the studies included in this meta-analysis. This tool is designed for use in comparative studies; however, because none of the included studies were controlled, we assessed study risk of bias based on selected items from the tool, focusing on the following questions: 1) did the study include all patients or consecutive patients versus a selected sample?; 2) was the study retrospective or prospective?; 3) was angio-




FIG 1. Search strategy results.

graphic and clinical follow-up satisfactory, thus allowing for ascertainment of all outcomes?; 4) were outcomes clearly reported?; and, 5) were the interventionalists treating the patients the same as those who assessed angiographic and clinical outcomes?

Statistical Analysis

We estimated from each study the cumulative incidence (event rate at the end of the study) and 95% CI. Because we anticipated marked heterogeneity in the populations and interventions across the various included studies, a random-effects model was used to pool incidence rates across studies.¹⁴ Variance was estimated by using the Freeman-Tukey double arcsine method.¹⁵ The I^2 statistic was used to express the proportion of inconsistency that is not attributable to chance.¹⁶ Analysis was conducted by using STATA Statistical Software: Release 14 (StataCorp, College Station, Texas).

RESULTS

Study Selection and Characteristics

The initial literature search yielded 106 articles. Upon review of the abstracts and titles, 90 articles were excluded. Sixteen articles were selected for full-text screening. In total, 15 studies including 565 patients with 588 aneurysms were included. Of these, 127 aneurysms (22%) were ruptured and 461 aneurysms (78%) were unruptured; in no case was the rupture status unknown. There were 470 aneurysms (80%) in the anterior circulation and 118 (20%) in the posterior circulation. Seventy-three aneurysms (12.0%) were treated with adjunctive coiling, stent placement, or stent-assisted coiling. Type of pre- and postoperative antiplatelet therapy varied widely between studies.

Of the 15 studies, 6 had a low risk of bias, 3 had a high risk of bias, and 6 had a moderate risk of bias. The smallest study had 6 patients with 6 aneurysms, and the largest study had 90 patients with 98 aneurysms. Eleven studies had angiographic follow-up at 6 months or longer. A summary of included studies is provided in the On-line Table. Flow chart for study selection is provided in Fig 1.

Overall Outcomes

The WEB treatment outcomes are presented in Table 1. Initial complete occlusion rates and adequate occlusion rates were 27% (95% CI, 15%–39%) and 59% (95% CI, 39%–78%), respectively.

Midterm complete occlusion rates after a median of 7 months were 39% (95% CI, 26%–52%) and midterm adequate occlusion rates were 85% (95% CI, 78%–91%) (Fig 2). Treatment failure occurred in 3% of cases (95% CI, 1%–6%). Perioperative morbidity and mortality rates were 4% (95% CI, 1%–8%) and 1% (95% CI, 0%–2%), respectively. The rate of thromboembolic complications was 8% (95% CI, 5%–12%). Midterm good neurologic outcome rates are provided in Fig 3.

Angiographic and Clinical Outcomes by Rupture Status

The rate of midterm complete occlusion was 45% (95% CI, 25%–65%) for the ruptured group and 22% (11%–33%) for the unruptured group ($P = .008$). The rate of midterm adequate occlusion for ruptured aneurysms was 85% (95% CI, 67%–98%), compared

with 84% (95% CI, 72%–94%) for unruptured aneurysms ($P = .89$). Data on initial occlusion by rupture status were not consistently reported, and no meta-analysis could be performed for this outcome.

Patients with ruptured aneurysms had similar rates of perioperative morbidity as those with unruptured aneurysms (2%; 95% CI, 0%–26% versus 2%; 95% CI, 0%–6%, respectively; $P = .35$). Rates of intraoperative rupture in ruptured and unruptured aneurysms were 6% (95% CI, 0%–11%) and 1% (95% CI, 0%–3%), respectively ($P = .08$). Treatment failure occurred at a higher rate for unruptured aneurysms (6%; 95% CI, 3%–9%) compared with the ruptured aneurysms (0%; 95% CI, 0%–4%) ($P = .04$). These results are presented in Table 2.

Table 1: Summary of outcomes

Outcome	Event Rate (%) (95% CI)	Raw Proportion
Initial complete occlusion	27 (15–39) ^a	76/277
Initial adequate occlusion	59 (39–78) ^a	132/277
Midterm complete occlusion	39 (26–52) ^a	168/362
Midterm adequate occlusion	85 (78–91)	209/261
Midterm good neurologic outcome	96 (94–98)	328/346
Intraoperative rupture	1 (0–2)	12/556
Perioperative morbidity	4 (1–8) ^a	29/449
Perioperative mortality	1 (0–2)	13/517
Thromboembolic complication	8 (5–12)	56/556
Retreatment	6 (1–12) ^a	37/501
Treatment failure	3 (1–6)	27/543

^a Indicates I^2 value above 50% (substantial heterogeneity).

DISCUSSION

This systematic review and meta-analysis of 15 uncontrolled studies demonstrated that treatment of wide-neck bifurcation aneurysms with the WEB device was achieved with high rates of technical success and low rates of complications. Initial adequate occlusion rate was nearly 60%, and adequate occlusion rate at follow-up was 85%. There were no substantial differences in outcomes by rupture status. These findings are important because they suggest that the WEB device might be a valuable tool in the treatment of wide-neck bifurcation aneurysms regardless of rupture status.

As demonstrated by this meta-analysis, a number of prior studies have examined the safety and efficacy of the WEB device. In a systematic review of 6 studies by Armoiry et al,¹⁷ the authors reported high rates of treatment feasibility (93%–100%) with ad-




FIG 2. Midterm adequate occlusion rates overall.




FIG 3. Midterm good neurologic outcome rates.

Table 2: Outcomes by rupture status

Outcome	Ruptured Group Event Rate (%) (95% CI)	Raw Proportion	Unruptured Group Event Rate (%) (95% CI)	Raw Proportion	P Value
Initial adequate occlusion	100 (57–100)	4/4	70 (44–91)	49/73	.24
Midterm complete occlusion	45 (25–65)	18/35	22 (11–33)	22/89	.008
Midterm adequate occlusion	85 (67–98)	33/44	84 (72–94)	76/118	.89
Intraoperative rupture	6 (0–11)	4/79	1 (0–3)	3/220	.08
Perioperative morbidity	2 (0–26) ^a	14/70	2 (0–6)	5/145	.35
Perioperative mortality	15 (7–23)	11/69	0 (0–3)	0/122	<.0001
Thromboembolic complication	21 (0–56) ^a	10/79	5 (2–10)	17/220	.07
Retreatment	4 (0–20)	7/66	7 (0–25) ^a	17/171	.71
Treatment failure	0 (0–3.9)	0/79	6 (3–9)	18/274	.04
Midterm good neurologic outcome	100 (97–100)	36/39	99 (94–100)	80/82	.21

^a Indicates I² value above 50% (substantial heterogeneity).

equate occlusion rates between 65% and 85% at midterm follow-up. Permanent morbidity rates ranged from 2%–7% depending on the series, and mortality ranged from 0%–17%. Our study differs from the systematic review performed by Armoiry et al¹⁷ in that we conducted a formal meta-analysis and were able to pool data from 15 studies including over 550 patients. By doing so, we were able to report efficacy and complication rates with narrow confidence intervals and provide important subgroup analyses of outcomes by rupture status.

Midterm occlusion rates with the WEB device were slightly higher than those reported for stent-assisted coil treatment of wide-neck bifurcation intracranial aneurysms. Typical long-term complete or near-complete occlusion rates for coiling of wide-neck and bifurcation aneurysms is generally on the order of 70%.^{18–20} One recently published meta-analysis of over 2000 patients undergoing stent-assisted coiling of wide-neck bifurcation aneurysms found long-term occlusion rates of 73%.²¹ Meanwhile, our study found a long-term adequate occlusion rate of 80%. Initial occlusion rates were approximately 60% with the

WEB device, compared with 54% for stent-assisted coiling of wide-neck bifurcation aneurysms. In addition to improved occlusion rates, a distinct advantage of treatment with the WEB device compared with stent-assisted coiling is the fact that pre- and/or intraoperative antiplatelet therapy is generally not required for WEB treatment. This is particularly important in the treatment of ruptured aneurysms.

Given the short length of follow-up available in many of the included studies (median of 7 months), the angiographic outcomes of the WEB device are generally similar to flow diversion. Complete occlusion rates in studies reporting 6–12 month follow-up for flow diversion typically range from 70%–93%.^{22–26} One large meta-analysis of 1451 patients with 1654 aneurysms treated with flow diverters found complete occlusion rates of 76%, with a vast amount of studies reporting follow-up after less than 12 months, similar to our results. In general, occlusion rates with flow diversion improve with increased follow-up as studies with 24 months or more of follow-up report occlusion rates over 90%.^{26–28} Similar to flow-diversion therapy, occlusion rates with

the WEB device generally increase with time because the healing process after placement of an intra-aneurysmal flow diverter involves a complex process of loose connective tissue deposition followed by endothelialization of the device–neck interface. Given the lack of consistent long-term (ie, >12 months) follow-up in the studies included in this meta-analysis, it is possible that we are in fact underestimating long-term occlusion rates.

This systematic review also demonstrated that complication rates associated with the WEB device were relatively low. Among unruptured aneurysms, perioperative morbidity rates were less than 3% despite a thromboembolic and iatrogenic rupture rate of 9%. Ruptured aneurysms had higher complication rates, which are likely due in part to preoperative morbidity and aneurysm complexity. Perioperative morbidity and mortality rates for stent-assisted coiling of unruptured aneurysms are similar, ranging from 3%–5% depending on the study.^{29,30} One recently published meta-analysis of stent-assisted coiling of wide-neck and bifurcation aneurysms found procedure-related morbidity and mortality rates of 3% and 1%, respectively.²¹ However, these conventional techniques are associated with poorer long-term angiographic outcomes and are hampered by the need for perioperative dual antiplatelet therapy, a factor that is particularly important in the treatment of ruptured aneurysms.^{31,32} Permanent morbidity and mortality rates related to flow-diverter treatment range from 8%–10%.³³ Thus, our findings suggest that the WEB device has a safety profile similar to flow diversion.

Limitations

The main limitation of this meta-analysis is that all the included studies were uncontrolled and many were retrospective. Many were also single-center and reported a wide variety of aneurysm morphologies and patient scenarios. There also might be variability in practice patterns and operator and medical center expertise. This is evident by the wide range of antiplatelet therapy regimens that were administered to patients before and after WEB treatment. There remains the possibility that there could be overlap in patients among studies. Although we were careful to exclude studies that had overlapping patient populations by examining the time periods studied and institutions where the patients were treated, in some cases, articles were not clear as to whether patients included in their studies were included in prior publications or in larger registries. The mean length of follow-up in the reviewed literature was modest. Another limitation is the lack of stratification of outcomes based on important variables such as type and size of the WEB device in many of the included studies. Publication bias is quite likely, and the role of the device manufacturer in the research is not fully clear. Lastly, we do not have data on baseline patient morbidity. Thus, we are unable to determine what proportion of patients with poor neurologic function at follow-up developed this after the procedure. Therefore, the overall certainty in the evidence at present is rated very low.³⁴

CONCLUSIONS

Our meta-analysis of 15 studies including over 500 patients with over 500 aneurysms treated with the WEB device demonstrated

that the WEB device has a safety profile similar to other endovascular devices such as coils and flow diverters. Furthermore, the WEB device is associated with satisfactory midterm angiographic adequate occlusion rates. These findings are particularly important given the complexity of aneurysms treated. Further prospective clinical trials, including clinical trials comparing WEB device treatment with conventional endovascular and surgical techniques, are needed to confirm these results and better define the risks and benefits of using the WEB device in treatment of wide-neck and wide-neck bifurcation aneurysms.

Disclosures: Laurent Pierot—RELATED: Consulting Fee or Honorarium: Sequent; UNRELATED: Consultancy: Blockade, Medtronic, Microvention, Neural, Penumbra. David F. Kallmes—UNRELATED: Board Membership: GE Healthcare,* Comments: cost-effectiveness board; Consultancy: Medtronic,* Comments: clinical trials planning and implementation; Grants/Grants Pending: Sequent Medical,* Microvention,* Codman,* Medtronic,* NeuroSigma,* Surmodics,* Comments: preclinical research and clinical trials support; Travel/Accommodations/Meeting Expenses Unrelated to Activities Listed: Medtronic,* Comments: presentation at FDA panel meeting. *Money paid to the institution.

REFERENCES

- Moret J, Cognard C, Weill A, et al. The “remodelling technique” in the treatment of wide neck intracranial aneurysms: angiographic results and clinical follow-up in 56 cases. *Interv Neuroradiol* 1997;3:21–35 Medline
- Nakahara T, Hidaka T, Kutsuna M, et al. Intraaneurysmal embolization for wide-necked aneurysms: remodeling technique, combined neck-clipping and coiling therapy, scaffolding technique. *Interv Neuroradiol* 2000;6(suppl 1):95–101 Medline
- Biondi A, Janardhan V, Katz JM, et al. Neuroform stent-assisted coil embolization of wide-neck intracranial aneurysms: strategies in stent deployment and midterm follow-up. *Neurosurgery* 2007;61:460–68; discussion 468–69 CrossRef Medline
- Mu SQ, Yang XJ, Li YX, et al. Endovascular treatment of wide-necked intracranial aneurysms using of “remodeling technique” with the HyperForm balloon. *Chin Med J (Engl)* 2008;121:725–29 Medline
- Lee JY, Seo JH, Cho YD, et al. Endovascular treatment of wide-neck intracranial aneurysms using a microcatheter protective technique: results and outcomes in 75 aneurysms. *AJNR Am J Neuroradiol* 2011;32:917–22 CrossRef Medline
- Pierot L, Cognard C, Spelle L, et al. Safety and efficacy of balloon remodeling technique during endovascular treatment of intracranial aneurysms: critical review of the literature. *AJNR Am J Neuroradiol* 2012;33:12–15 CrossRef Medline
- Pierot L, Wakhloo AK. Endovascular treatment of intracranial aneurysms: current status. *Stroke* 2013;44:2046–54 CrossRef Medline
- Ding YH, Lewis DA, Kadirvel R, et al. The Woven EndoBridge: a new aneurysm occlusion device. *AJNR Am J Neuroradiol* 2011;32:607–11 CrossRef Medline
- Pierot L, Liebig T, Sychra V, et al. Intracapsular flow-disruption treatment of intracranial aneurysms: preliminary results of a multicenter clinical study. *AJNR Am J Neuroradiol* 2012;33:1232–38 CrossRef Medline
- Lubicz B, Klisch J, Gauvrit JY, et al. WEB-DL endovascular treatment of wide-neck bifurcation aneurysms: short- and midterm results in a European study. *AJNR Am J Neuroradiol* 2014;35:432–38 CrossRef Medline
- Papagiannaki C, Spelle L, Januel AC, et al. WEB intracapsular flow disruptor—prospective, multicenter experience in 83 patients with 85 aneurysms. *AJNR Am J Neuroradiol* 2014;35:2106–11 CrossRef Medline
- Liebig T, Kabbasch C, Strasilla C, et al. Intracapsular flow disruption in acutely ruptured aneurysms: a multicenter retrospective review of the use of the WEB. *AJNR Am J Neuroradiol* 2015;36:1721–27 CrossRef Medline

13. Pierot L, Moret J, Turjman F, et al. **WEB treatment of intracranial aneurysms: clinical and anatomic results in the French observatory.** *AJNR Am J Neuroradiol* 2016;37:655–69 [CrossRef Medline](#)
14. DerSimonian R, Laird N. **Meta-analysis in clinical trials.** *Control Clin Trials* 1986;7:177–88 [CrossRef Medline](#)
15. Barendregt JJ, Doi SA, Lee YY, et al. **Meta-analysis of prevalence.** *J Epidemiol Community Health* 2013;67:974–78 [CrossRef Medline](#)
16. Higgins JP, Thompson SG, Deeks JJ, et al. **Measuring inconsistency in meta-analyses.** *BMJ* 2003;327:557–60 [CrossRef Medline](#)
17. Armoiry X, Turjman F, Hartmann DJ, et al. **Endovascular treatment of intracranial aneurysms with the WEB device: a systematic review of clinical outcomes.** *AJNR Am J Neuroradiol* 2016;37:868–72 [CrossRef Medline](#)
18. Pierot L, Spelle L, Vitry F. **Immediate anatomic results after the endovascular treatment of unruptured intracranial aneurysms: analysis of the ATENA series.** *AJNR Am J Neuroradiol* 2010;31:140–44 [CrossRef Medline](#)
19. Pierot L, Cognard C, Ricolfi F, et al. **Immediate anatomic results after the endovascular treatment of ruptured intracranial aneurysms: analysis in the CLARITY series.** *AJNR Am J Neuroradiol* 2010;31:907–11 [CrossRef Medline](#)
20. Brinjikji W, Murad MH, Lanzino G, et al. **Endovascular treatment of intracranial aneurysms with flow diverters: a meta-analysis.** *Stroke* 2013;44:442–47 [CrossRef Medline](#)
21. Zhao B, Yin R, Lanzino G, et al. **Endovascular coiling of wide-neck and wide-neck bifurcation aneurysms: a systematic review and meta-analysis.** *AJNR Am J Neuroradiol* 2016 Jun 2. [Epub ahead of print] [CrossRef Medline](#)
22. Puffer RC, Piano M, Lanzino G, et al. **Treatment of cavernous sinus aneurysms with flow diversion: results in 44 patients.** *AJNR Am J Neuroradiol* 2014;35:948–51 [CrossRef Medline](#)
23. Moon K, Albuquerque F, Ducruet AF, et al. **Resolution of cranial neuropathies following treatment of intracranial aneurysms with the Pipeline embolization device.** *J Neurosurg* 2014;121:1085–92 [CrossRef Medline](#)
24. Szikora I, Berentei Z, Kulcsar Z, et al. **Treatment of intracranial aneurysms by functional reconstruction of the parent artery: the Budapest experience with the Pipeline embolization device.** *AJNR Am J Neuroradiol* 2010;31:1139–47 [CrossRef Medline](#)
25. Lylyk P, Miranda C, Ceratto R, et al. **Curative endovascular reconstruction of cerebral aneurysms with the Pipeline embolization device: the Buenos Aires experience.** *Neurosurgery* 2009;64:632–42; discussion 642–43; quiz N6 [CrossRef Medline](#)
26. Nelson PK, Lylyk P, Szikora I, et al. **The Pipeline embolization device for the intracranial treatment of aneurysms trial.** *AJNR Am J Neuroradiol* 2011;32:34–40 [CrossRef Medline](#)
27. Briganti F, Napoli M, Leone G, et al. **Treatment of intracranial aneurysms by flow diverter devices: long-term results from a single center.** *Eur J Radiol* 2014;83:1683–90 [CrossRef Medline](#)
28. Saatci I, Yavuz K, Ozer C, et al. **Treatment of intracranial aneurysms using the Pipeline flow-diverter embolization device: a single-center experience with long-term follow-up results.** *AJNR Am J Neuroradiol* 2012;33:1436–46 [CrossRef Medline](#)
29. Ryu CW, Park S, Shin HS, et al. **Complications in stent-assisted endovascular therapy of ruptured intracranial aneurysms and relevance to antiplatelet administration: a systematic review.** *AJNR Am J Neuroradiol* 2015;36:1682–88 [CrossRef Medline](#)
30. Hong Y, Wang YJ, Deng Z, et al. **Stent-assisted coiling versus coiling in treatment of intracranial aneurysm: a systematic review and meta-analysis.** *PLoS One* 2014;9:e82311 [CrossRef Medline](#)
31. Pierot L, Spelle L, Vitry F. **Immediate clinical outcome of patients harboring unruptured intracranial aneurysms treated by endovascular approach: results of the ATENA study.** *Stroke* 2008;39:2497–504 [CrossRef Medline](#)
32. Cognard C, Pierot L, Anxionnat R, et al. **Results of embolization used as the first treatment choice in a consecutive nonselected population of ruptured aneurysms: clinical results of the Clarity GDC study.** *Neurosurgery* 2011;69:837–41; discussion 842 [CrossRef Medline](#)
33. Kallmes DF, Hanel R, Lopes D, et al. **International retrospective study of the Pipeline embolization device: a multicenter aneurysm treatment study.** *AJNR Am J Neuroradiol* 2015;36:108–15 [CrossRef Medline](#)
34. Murad MH, Montori VM, Ioannidis JP, et al. **How to read a systematic review and meta-analysis and apply the results to patient care: users' guides to the medical literature.** *JAMA* 2014;312:171–79 [CrossRef Medline](#)
35. Behme D, Berlis A, Weber W. **Woven EndoBridge intrasaccular flow disrupter for the treatment of ruptured and unruptured wide-neck cerebral aneurysms: report of 55 cases.** *AJNR Am J Neuroradiol* 2015; 36:1501–06 [CrossRef Medline](#)
36. Bozzetto Ambrosi P, Gory B, Sivan-Hoffmann R, et al. **Endovascular treatment of bifurcation intracranial aneurysms with the WEB SL/SLS: 6-month clinical and angiographic results.** *Interv Neuroradiol* 2015;21:462–69 [CrossRef Medline](#)
37. Caroff J, Mihalea C, Dargento F, et al. **Woven Endobridge (WEB) device for endovascular treatment of ruptured intracranial wide-neck aneurysms: a single-center experience.** *Neuroradiology* 2014; 56:755–61 [CrossRef Medline](#)
38. Caroff J, Mihalea C, Klisch J, et al. **Single-Layer WEBs: intrasaccular flow disrupters for aneurysm treatment—feasibility results from a European study.** *AJNR Am J Neuroradiol* 2015;36:1942–46 [CrossRef Medline](#)
39. Cognard C, Januel AC. **Remnants and recurrences after the use of the WEB intrasaccular device in large-neck bifurcation aneurysms.** *Neurosurgery* 2015;76:522–30; discussion 530 [CrossRef Medline](#)
40. Gherasim DN, Gory B, Sivan-Hoffmann R, et al. **Endovascular treatment of wide-neck anterior communicating artery aneurysms using WEB-DL and WEB-SL: short-term results in a multicenter study.** *AJNR Am J Neuroradiol* 2015;36:1150–54 [CrossRef Medline](#)
41. Lubicz B, Mine B, Collignon L, et al. **WEB device for endovascular treatment of wide-neck bifurcation aneurysms.** *AJNR Am J Neuroradiol* 2013;34:1209–14 [CrossRef Medline](#)
42. Pierot L, Klisch J, Cognard C, et al. **Endovascular WEB flow disruption in middle cerebral artery aneurysms: preliminary feasibility, clinical, and anatomical results in a multicenter study.** *Neurosurgery* 2013;73:27–34; discussion 34–35 [CrossRef Medline](#)
43. Pierot L, Spelle L, Molyneux A, et al. **Clinical and anatomical follow-up in patients with aneurysms treated with the WEB device: 1-year follow-up report in the cumulated population of 2 prospective, multicenter series (WEBCAST and French Observatory).** *Neurosurgery* 2016;78:133–41 [CrossRef Medline](#)
44. Pierot L, Costalat V, Moret J, et al. **Safety and efficacy of aneurysm treatment with WEB: results of the WEBCAST study.** *J Neurosurg* 2016;1250–56 [CrossRef Medline](#)
45. Lescher S, du Mesnil de Rochemont R, Berkefeld J. **Woven Endobridge (WEB) device for endovascular treatment of complex unruptured aneurysms: a single center experience.** *Neuroradiology* 2016;58:383–90 [CrossRef Medline](#)